Assessing the Effect of Apremilast on Serum Leptin levels in Obese Patients with Psoriasis
Background: Psoriasis is a common inflammatory condition worldwide, with an average prevalence ranging from 2% to 3%. However, the incidence of psoriasis varies among different ethnic groups and regions. Elevated leptin levels have been associated with increased cellular proliferation, including T-...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Baghdad/ Al-Kindy College of Medicine
2024-12-01
|
| Series: | مجله كليه طب الكندي |
| Subjects: | |
| Online Access: | https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/1230 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Psoriasis is a common inflammatory condition worldwide, with an average prevalence ranging from 2% to 3%. However, the incidence of psoriasis varies among different ethnic groups and regions. Elevated leptin levels have been associated with increased cellular proliferation, including T-cells. Additionally, high leptin levels may stimulate the synthesis of proinflammatory cytokines such as ILـ6 and TNFـα.
Objectives: To evaluate the effect of Apremilast on Leptin in obese psoriatic patients.
Subjects and Methods: Thirty patients with psoriasis were included in This prospective cohort study to measure the levels of serum Leptin by using the ELISA technique, before and after receiving Apremilast.
Result: The present work found the concentration of Leptin before receiving Apremilast was 2.365 ng/ml, and after six months from baseline, it was reduced to 1.933 ng/ml, which was statistically significant (P<0.05).
Conclusion: This prospective cohort study provides evidence that Apremilast can decrease elevated Leptin levels in individuals diagnosed with psoriasis. The study observed a 0.42 ng/ml reduction in Leptin levels after 6 months of Apremilast treatment.
|
|---|---|
| ISSN: | 1810-9543 2521-4365 |